Dr. Faller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
Moakley, 3rd Floor
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1981 - 1983
University of California (San Francisco)Residency, Internal Medicine, 1979 - 1981
Harvard Medical SchoolClass of 1979
Certifications & Licensure
CA State Medical License 1980 - Present
MA State Medical License 1982 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1989
Clinical Trials
- Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Start of enrollment: 1997 Sep 01
- Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus Start of enrollment: 1994 Dec 01
Publications & Presentations
PubMed
- A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?Yulia Sidi, Cassie Dong, Yujun Wu, Douglas V Faller
Leukemia Research. 2024-03-01 - 4 citationsA randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.Sileny N Han, Amit Oza, Nicoletta Colombo, Ana Oaknin, Francesco Raspagliesi
Gynecologic Oncology. 2023-11-01 - 9 citationsEpilepsy: Mitochondrial connections to the 'Sacred' disease.Walter H Moos, Douglas V Faller, Ioannis P Glavas, Iphigenia Kanara, Krishna Kodukula
Mitochondrion. 2023-09-01
Abstracts/Posters
- Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...Douglas V. Faller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...Douglas V. Faller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
ORYZON Announces First Patient in in NET, a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine CarcinomasJanuary 18th, 2023- ORYZON Presents Final Data from Phase IIa ALICE Trial in Unfit AML Patients with First-Line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022December 12th, 2022
- ORYZON to Present Preliminary Blinded Aggregate Safety Data from Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality DisorderSeptember 16th, 2022
- Join now to see all
Grant Support
- Mechanisms Of Action And Signaling By Steroid Hormone AntagonistsNational Cancer Institute2009–2012
- Boston University Cross-Disciplinary Training In Nanotechnology For CancerNational Cancer Institute2010–2011
- Inducing Chromosomal Damage Responses In Pancreatic CancerNational Cancer Institute2009–2010
- Development Of An Oncogene-Targeted TherapeuticNational Cancer Institute2009
- RAS Oncoprotein-Targeted Therapy For CancerNational Cancer Institute2005–2009
- Signal Transduction By Androgen In Prostate CellsNational Cancer Institute2004–2007
- Development Of A Ras-Targeted Cancer TherapeuticNational Cancer Institute2004
- Control Of Cell Growth By Short-Chain Fatty AcidsNational Cancer Institute2000–2004
- Oral Therapeutic For Beta-ThalassemiaNational Institute Of Diabetes And Digestive And Kidney Diseases2003
- Oral Therapeutic For Inducing Fetal HemoglobinNational Heart, Lung, And Blood Institute2002–2003
- Oral Therapeutics For Viral MalignanciesNational Cancer Institute2002–2003
- Oncobiology Training ProgramNational Cancer Institute1994–2003
- Anti Viral Therapeutic For EBV MalignanciesNational Cancer Institute2001–2002
- Cancer Research CenterNational Cancer Institute1999–2002
- Arginine Butyrate For Treatment Of Leg Ulcer In Patients With Sickle Cell DiseaseNational Center For Research Resources2001
- Arginine Butyrate Therapy--Leg Ulcer In Sickle Cell DISENational Center For Research Resources2000
- Control Of Cell Growth By OncogenesNational Cancer Institute1991–2000
- Oral Agents To Induce Fetal HemoglobinNational Heart, Lung, And Blood Institute1999
- Oral Therapeutics For Viral MalignanciesNational Cancer Institute1999
- Molecular Basis Of Htlv1 Induced ArthropathyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997–1999
- Detection Of Premaligancy In Breast Biopsy SpecimensNational Cancer Institute1996
- Trans Activation Of B Cell Mitogen Cytokine Genes By HIVNational Cancer Institute1994–1996
- Isobutyramide For Increasing Fetal Hemoglobin In Beta GlobinopathiesNational Center For Research Resources1994–1995
- Clinical Trials Of Butyrate Analogs In Beta HemoglobinopathiesNational Center For Research Resources1994–1995
- Mechanisms Of Vasoocclusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1994
- Mechanisms Of Vaso-Occlusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1991–1993
- Mechanisms Of Vaso-Occlusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1990–1991
- Control Of Cell Growth By OncogenesNational Cancer Institute1990–1991
- Tumor-Specific CTL Recognition Of Transfected CellsNational Cancer Institute1985–1988
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
